
Bactobio is a biotechnology company focused on unlocking the potential of unculturable microbes through genomics, machine learning, and bioengineering. Their innovative approach aims to discover novel antimicrobials for healthcare and agriculture, addressing critical global challenges such as antimicrobial resistance and environmental sustainability. With a commitment to creating a safer and greener world, Bactobio leverages advanced technologies to develop biodegradable and effective solutions, positioning itself as a leader in the microbial revolution.

Bactobio is a biotechnology company focused on unlocking the potential of unculturable microbes through genomics, machine learning, and bioengineering. Their innovative approach aims to discover novel antimicrobials for healthcare and agriculture, addressing critical global challenges such as antimicrobial resistance and environmental sustainability. With a commitment to creating a safer and greener world, Bactobio leverages advanced technologies to develop biodegradable and effective solutions, positioning itself as a leader in the microbial revolution.
Founded: May 2020
Headquarters: London, United Kingdom
Focus: Using genomics, machine learning and synthetic biology to culture unculturable microbes and discover novel antimicrobials and agricultural bioprotection
Employees (approx.): 54
Total disclosed funding: 12,615,208 USD
Antimicrobial discovery and agricultural bioprotection (culturing unculturable microbes to find new bioactive chemistries).
2020
Biotechnology Research
6,000,000 GBP
Oversubscribed bridge round closed Dec 1, 2022
2,800,000 GBP
Funding round announced Oct 1, 2021 (rebranding to Bactobio)
“Led by Bridford Group for the Dec 2022 bridge/convertible round; company lists angel/advisor investors including Peder Holk Nielsen, Hugh Grant, Jonathan Milner and Claudio Costamagna”
| Company |
|---|